{"gene":"ZNF384","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":2000,"finding":"CIZ (ZNF384) was identified as a novel protein that binds the SH3 domain of p130(Cas) via far-Western screening. CIZ co-localizes at focal adhesions and in the nucleus, and acts as a nucleocytoplasmic shuttling protein (demonstrated by transient interspecies heterokaryon formation assay). CIZ binds DNA with consensus sequence (G/C)AAAAA(A) as determined by cyclic amplification and selection of targets (CAST) analysis, and specifically binds the MMP-1 promoter. Overexpression of CIZ upregulates transcription from MMP-1, MMP-3, and MMP-7 promoters, with transactivation enhanced in the presence of Cas.","method":"Far-Western screening, heterokaryon shuttling assay, CAST/SELEX DNA binding consensus, promoter-reporter assays, co-immunoprecipitation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (far-Western, CAST, heterokaryon assay, promoter-reporter, Co-IP) in a single foundational study; founding paper for the protein","pmids":["10669742"],"is_preprint":false},{"year":2000,"finding":"NP/NMP4 (ZNF384) proteins localize to distinct nuclear matrix subdomains in osteoblasts. The zinc finger domain was shown to be both necessary and sufficient for nuclear import and nuclear matrix targeting, as determined by immunofluorescence of GFP-NP/NMP4 fusion proteins.","method":"Immunofluorescence microscopy, GFP fusion protein localization, domain deletion analysis","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization with domain mapping using multiple constructs, single lab","pmids":["10972987"],"is_preprint":false},{"year":2001,"finding":"NP/NMP4/CIZ (ZNF384) binds to poly(dT) sequences (sites A and B) in the rat type I collagen alpha1(I) (COL1A1) promoter and bends the DNA. Mutation of sites A or B increased COL1A1 promoter activity in UMR-106 osteoblast-like cells. Overexpression of specific NMP4 clones repressed COL1A1 promoter activity, demonstrating that NMP4/CIZ functions as a transcriptional repressor of COL1A1.","method":"Expression library screening with site B probe, promoter-reporter constructs with site mutations, antibody disruption of DNA-protein complexes, overexpression assays","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (DNA binding, antibody disruption, promoter mutagenesis, overexpression in osteoblasts), single lab but comprehensive mechanistic dissection","pmids":["11149472"],"is_preprint":false},{"year":2000,"finding":"Overexpression of CIZ (ZNF384) in MC3T3E1 osteoblast-like cells increased focal adhesion plaque number, reduced cell proliferation, enhanced type I collagen mRNA expression, and upregulated a heterologous promoter driven by a CIZ-consensus binding sequence within the type I collagen gene promoter.","method":"Overexpression, promoter-reporter assay, RT-PCR, immunofluorescence","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — promoter binding confirmed, multiple phenotypic readouts, single lab","pmids":["11112339"],"is_preprint":false},{"year":2002,"finding":"Zinc fingers 2, 3, and 6 of Nmp4 mediate binding to the homopolymeric (dA.dT) COL1A1/MMP DNA consensus element (minor groove binding). The N-terminus has strong transactivation capacity when fused to GAL4 DBD, but this activity is masked in the full-length protein. Upon binding to the homopolymeric (dA.dT) element, native Nmp4 upregulates transcription, and the polyglutamine-alanine (poly(QA)) domain acquires a significant transactivation role, suggesting allosteric activation by DNA binding.","method":"GAL4 fusion transactivation assays, deletion mutagenesis of zinc fingers, promoter-reporter assays, in vitro DNA binding","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro DNA binding combined with domain mutagenesis and reporter assays; mechanistic dissection of activation domains","pmids":["11867614"],"is_preprint":false},{"year":2002,"finding":"CIZ/NMP4 (ZNF384) fuses with EWSR1 (via t(12;22)) or TAF15 (via t(12;17)) in acute leukemia. The resulting fusion proteins have transforming properties in NIH3T3 cells (focus formation assay), but do not affect the expression of CIZ target genes (MMP-1, COL1A1), suggesting oncogenic activity independent of normal CIZ transactivation.","method":"RT-PCR/cloning of fusion transcripts, NIH3T3 focus formation assay, target gene expression analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transformation assay plus target gene expression, replicated across two fusion types, single lab","pmids":["12359745"],"is_preprint":false},{"year":2004,"finding":"Nmp4/CIZ (ZNF384) binds an electrophoretically confirmed cis-element within the MMP-13 PTH response region (-119/-110 nt homopolymeric dA:dT). Mutation of this element decreases basal MMP-13 promoter activity but enhances its PTH/PGE2 responsiveness. Overexpression of Nmp4/CIZ enhances basal MMP-13 promoter activity but diminishes hormone-induced induction.","method":"EMSA (electrophoretic mobility shift assay), promoter-reporter mutagenesis, overexpression assays in osteoblasts","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — EMSA binding combined with promoter mutagenesis and overexpression, multiple orthogonal methods, mechanistically defined role","pmids":["15026307"],"is_preprint":false},{"year":2004,"finding":"CIZ/Nmp4 knockout mice show increased spermatogenic cell apoptosis and variable degrees of spermatogenic cell degeneration in seminiferous tubules, resulting in male infertility in some mice. CIZ/Nmp4 co-localizes with Smad1 in the testis, suggesting it modulates BMP signaling in spermatogenesis.","method":"Gene knockout (disruption by beta-galactosidase/neomycin insertion in exon 2), histological analysis, TUNEL assay, immunolocalization","journal":"Genes to cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout with specific cellular phenotype (apoptosis by TUNEL) and co-localization with Smad1, single lab","pmids":["15189450"],"is_preprint":false},{"year":2005,"finding":"CIZ-deficient mice show increased bone volume and bone formation rates without changes in bone resorption. CIZ deficiency enhances BMP-2-induced osteoblastic differentiation of bone marrow cells, and BMP-2-induced bone formation on calvariae in vivo is enhanced in CIZ-null mice. This establishes that CIZ (ZNF384) suppresses adult bone mass by inhibiting BMP signaling-induced osteoblast activity.","method":"CIZ knockout mouse, bone histomorphometry, bone marrow cell cultures (ALP, mineralization), in vivo BMP-2 calvarial injection, mRNA expression analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout with multiple orthogonal in vivo and in vitro assays, replicated across multiple bone formation assays, single lab but comprehensive","pmids":["15781586"],"is_preprint":false},{"year":2005,"finding":"E2A-CIZ (TCF3-ZNF384) and VP16-CIZ fusion proteins transform NIH3T3 fibroblasts in focus formation assays. Deletion of the zinc fingers of CIZ abolished both DNA-binding and transforming properties of TAF15-CIZ, while deletion of other CIZ domains had no effect. E2A-CIZ and VP16-CIZ transactivate the MMP7 promoter in luciferase assays, indicating transformation involves ZNF384 zinc finger-mediated DNA binding and transactivation.","method":"NIH3T3 focus formation assay, domain deletion mutagenesis, luciferase reporter assay","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — domain deletion mutagenesis combined with transformation assay and reporter assay; mechanistically defines the required domains","pmids":["15669012"],"is_preprint":false},{"year":2005,"finding":"The mouse Nmp4/CIZ gene is driven by two adjacent promoters (P1 and P2) that initiate transcription of alternative first exons. Both promoters lack TATA/CCAAT boxes but contain initiator sites and CpG islands. PTH at low doses attenuates P1/P2 activity in osteoblast-like cells. The promoters are autoregulated, and deletion analysis identified positive and negative regulatory regions.","method":"Promoter-reporter assays, Northern blot, deletion analysis, PTH treatment","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter-reporter with deletion analysis and physiological stimulus, single lab","pmids":["15716059"],"is_preprint":false},{"year":2006,"finding":"Human ZNF384 does not interact with p130CAS directly (in contrast to rat CIZ). Instead, yeast two-hybrid screening identified zyxin, PCBP1, and vimentin as ZNF384 binding partners in human cells. Zyxin can interact with p130CAS, suggesting that zyxin mediates an indirect interaction between ZNF384 and p130CAS in human cells.","method":"Yeast two-hybrid screening","journal":"Experimental cell research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid only, no orthogonal validation of interactions, single lab","pmids":["16510139"],"is_preprint":false},{"year":2007,"finding":"Nmp4/CIZ (ZNF384) contributes to fluid shear stress (FSS)-induced MMP-13 transcription. FSS decreased Nmp4/CIZ binding to its cis-element in the MMP-13 PTH response region (measured by EMSA), and mutation of this element abolished FSS-induced MMP-13 promoter activity. FSS also enhanced Nmp4/CIZ promoter activity and induced p130(Cas) nuclear translocation.","method":"EMSA, promoter-reporter assay with mutation, fluid shear stress application, RT-qPCR","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and promoter mutagenesis with physiological mechanical stimulus, multiple readouts, single lab","pmids":["17455210"],"is_preprint":false},{"year":2007,"finding":"CIZ (ZNF384) deficiency blocks unloading-induced reduction in osteoblastic bone formation parameters in vivo. CIZ-deficient mice resist tail suspension-induced bone loss. Bone marrow cell cultures from unloaded CIZ-null mice maintain mineralized nodule formation, which is suppressed in wild-type unloaded mice, demonstrating CIZ acts in mechanosensory signaling in bone.","method":"Tail suspension (unloading) model, bone histomorphometry, bone marrow cell cultures, mineralized nodule formation assay","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse with in vivo and in vitro mechanistic validation, single lab","pmids":["17301008"],"is_preprint":false},{"year":2008,"finding":"Yeast two-hybrid screening of Ciz (ZNF384) binding partners revealed that 47% of positive clones encode extracellular matrix proteins, including Col1a1, Col1a2, Fbln2, and Rpsa. In vitro co-immunoprecipitation using in vitro-translated proteins showed direct binding of Ciz-deltaZF (lacking zinc fingers) to C-propeptides of Col1a1 and Col1a2. In vivo co-immunoprecipitation of transfected Ciz and C-propeptide of Col1a1 was confirmed in COS-7 cells. C-propeptides and Ciz co-localize in the nucleus when overexpressed.","method":"Yeast two-hybrid, in vitro translation + co-IP, in vivo co-IP (COS-7 cells), co-localization immunofluorescence","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with both in vitro and in vivo systems, single lab","pmids":["18211825"],"is_preprint":false},{"year":2009,"finding":"Nmp4/CIZ knockout mice exhibit a significantly greater PTH-induced acquisition of femoral trabecular bone versus wild-type mice, establishing that Nmp4/CIZ suppresses PTH-mediated anabolic bone formation. The baseline phenotype showed modestly elevated bone mineral density in null mice.","method":"Nmp4-knockout mouse, PTH treatment, microCT, DEXA, histomorphometry","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with PTH challenge and multiple skeletal readouts, single lab","pmids":["19189321"],"is_preprint":false},{"year":2010,"finding":"Nmp4/CIZ (ZNF384) inhibits mechanically induced beta-catenin nuclear translocation in osteoblasts. In Nmp4-null osteoblasts exposed to oscillatory fluid shear stress (OFSS), nuclear translocation of beta-catenin, ERK, Akt, GSK3beta activity, and cyclin D1 expression are all enhanced. OFSS-induced cytoskeletal reorganization and focal adhesion formation are also qualitatively enhanced in Nmp4-null cells.","method":"Calvaria-derived osteoblasts from Nmp4-null mice, OFSS mechanical stimulation, nuclear/cytoplasmic fractionation, immunofluorescence, Western blot","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout cells with mechanical stimulation and multiple signaling pathway readouts, single lab","pmids":["20112285"],"is_preprint":false},{"year":2012,"finding":"CIZ/NMP4 (ZNF384) binds the RANKL promoter at an identified consensus site, activates RANKL transcription (luciferase assay), and overexpression of CIZ/NMP4 enhances B16 melanoma cell migration. RANKL treatment enhances CIZ/NMP4 expression, establishing a positive feedback loop. siRNA knockdown of CIZ/NMP4 suppresses B16 cell migration in Transwell assays.","method":"Transwell migration assay, siRNA knockdown, overexpression, luciferase reporter assay, RANKL promoter binding","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — promoter binding with luciferase plus functional migration assays with both knockdown and overexpression, single lab","pmids":["22307584"],"is_preprint":false},{"year":2015,"finding":"CIZ/NMP4 (ZNF384) deficiency in mice suppresses K/BxN serum-induced arthritis severity. CIZ/NMP4 was shown to bind the IL-1β promoter and activate its transcription (established by promoter binding and luciferase assay), and CIZ/NMP4 deficiency reduced arthritis-induced increases in IL-1β, RANKL, and MMP-3 mRNA.","method":"CIZ/NMP4 knockout mouse, K/BxN arthritis model, qPCR, histology, promoter binding/luciferase assay","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout with disease model plus promoter-binding mechanistic evidence, single lab","pmids":["26378628"],"is_preprint":false},{"year":2015,"finding":"ChIP-seq analysis of Nmp4 (ZNF384) in MC3T3-E1 preosteoblasts, murine embryonic stem cells, and blood cell lines identified Nmp4 target genes enriched for negative regulators of biosynthetic processes. ChIP-seq/gene ontology analysis and mRNA expression profiling in Nmp4-null vs. wild-type MSPCs suggest Nmp4 suppresses bone anabolism in part by regulating IGF-binding protein expression.","method":"ChIP-seq, RNA-seq/expression profiling, microCT, histomorphometry, FACS","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq with expression correlation, single lab; ChIP-seq establishes binding sites but downstream mechanism inferred from gene ontology","pmids":["26244796"],"is_preprint":false},{"year":2016,"finding":"NMP4 (ZNF384) binds two sites in the AQP5 (aquaporin 5) promoter region (at -1370/-1329 nt and -592/-602 nt) as demonstrated by EMSA. NMP4 overexpression increases AQP5 promoter activity (reporter assays with constructs -469 to -1979 nt) and increases AQP5 mRNA by 2.5-fold in HEK293 cells.","method":"EMSA, promoter-reporter assay, overexpression, RT-PCR in HEK293 cells","journal":"DNA and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and functional reporter assay with mRNA validation, single lab","pmids":["27058007"],"is_preprint":false},{"year":2019,"finding":"ZNF384 fusion proteins (EP300-ZNF384, SYNRG-ZNF384) exhibit stronger transcriptional activity on SALL4 and ID2 promoters/enhancers than wild-type ZNF384. GST pull-down assay showed ZNF384 fusion proteins bind EP300 (the coactivator) more strongly than wild-type ZNF384. Co-expression of EP300 specifically enhanced transcriptional activities of ZNF384 fusion proteins.","method":"GST pull-down, promoter/enhancer-reporter assay (luciferase), EP300 co-expression, transient transfection","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pull-down combined with reporter assays for multiple fusion proteins, single lab","pmids":["31234226"],"is_preprint":false},{"year":2019,"finding":"Loss of Nmp4 (ZNF384) in mesenchymal stem/progenitor cells enhances glycolytic conversion during osteogenic differentiation (a key metabolic step in bone anabolism) and increases collagen translation and secretion. RNA-seq of differentiating Nmp4-null MSPCs showed altered expression of >5,000 genes, with elevated matrix gene expression confirmed by biomechanical testing of bone samples.","method":"RNA-seq, metabolic assays (glycolysis measurement), collagen secretion assays, biomechanical bone testing, Nmp4-knockout mouse","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout + multiple orthogonal metabolic/secretory/mechanical assays, single lab","pmids":["30645175"],"is_preprint":false},{"year":2020,"finding":"NMP4 (ZNF384) binds to promoters and/or conserved non-coding sequences of chemokine genes (Ccl2, Ccl7, Cxcl1) and pro-inflammatory cytokine genes (Il1b, Il6) in mouse lung epithelial cells and macrophages, as demonstrated by ChIP. NMP4-deficient mice show significantly reduced expression of these genes and reduced recruitment of monocytes/neutrophils to the lungs during influenza A (H1N1) infection, with no effect on viral clearance.","method":"Nmp4-knockout mouse, influenza infection model, ChIP, qPCR, flow cytometry","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct promoter binding combined with knockout mouse with defined in vivo phenotype and multiple inflammatory readouts","pmids":["32152414"],"is_preprint":false},{"year":2021,"finding":"ZNF384 binds DNA ends in vitro and is recruited to DNA double-strand breaks (DSBs) in vivo. ZNF384 recruitment to DSBs requires PARP1-dependent chromatin expansion, followed by C2H2 zinc finger binding to exposed DNA. ZNF384 interacts with Ku70/Ku80 via its N-terminus (demonstrated by Co-IP), promoting Ku assembly and recruitment of downstream cNHEJ factors (APLF and XRCC4/LIG4) for efficient DSB repair.","method":"In vitro DNA-end binding assay, laser microirradiation/live-cell imaging (recruitment to DSBs), PARP1 inhibition, Co-IP (ZNF384–Ku70/Ku80), domain deletion analysis, NHEJ reporter assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution of DNA end binding, live-cell DSB recruitment assay, Co-IP with domain mapping, functional NHEJ reporter, multiple orthogonal methods","pmids":["34772923"],"is_preprint":false},{"year":2022,"finding":"ZNF384 fusion oncoproteins (FO) occupy a subset of predominantly intragenic/enhancer chromatin regions with increased histone 3 lysine acetylation and deregulate expression of hematopoietic stem cell transcription factors. In mouse and human HSPCs expressing ZNF384 FO, myeloid lineage skewing, hematopoietic expansion, and self-renewal occur. In human HSPCs, ZNF384 FO alone drove B/myeloid leukemia. An Ep300::Znf384 knockin mouse model confirmed these phenotypes.","method":"Viral expression in mouse/human HSPCs, Ep300::Znf384 knockin mouse, ChIP-seq (H3K27ac), RNA-seq, xenograft model, FLT3 inhibitor treatment in vivo","journal":"Blood cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq demonstrating direct chromatin occupancy, knockin mouse model, viral expression in primary cells, multiple orthogonal mechanistic assays","pmids":["35247902"],"is_preprint":false},{"year":2022,"finding":"ZNF384-rearranged ALL exclusively activates an intergenic enhancer element at the FLT3 locus through direct binding of the fusion protein, leading to enhancer-promoter looping and FLT3 overexpression. Downregulation of ZNF384 blunts FLT3 activation and decreases cell sensitivity to the FLT3 inhibitor gilteritinib in vitro. In ZNF384-rearranged xenograft models, gilteritinib shows significant anti-leukemia efficacy in vivo.","method":"ChIP-seq, chromatin conformation capture (enhancer-promoter looping), shRNA knockdown of ZNF384, luciferase/reporter assay, xenograft mouse model, gilteritinib treatment in vivo","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq + chromatin looping + functional knockdown + in vivo xenograft; multiple orthogonal methods establishing direct mechanistic link","pmids":["36104354"],"is_preprint":false},{"year":2022,"finding":"ZNF384 transactivates ZEB1 expression as shown by ChIP-qPCR and luciferase reporter assays, inducing EMT-like phenotype and promoting breast cancer metastasis. ZEB1 in turn upregulates ZNF384 expression by repressing miR-485-5p, forming a positive feedback loop.","method":"ChIP-qPCR, luciferase reporter assay, Transwell/scratch migration assays, xenograft mouse model","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirmed direct binding; luciferase reporter validates transactivation; functional migration assays; single lab","pmids":["36100877"],"is_preprint":false},{"year":2022,"finding":"Conditional loss of Nmp4 (ZNF384) from Prx1-expressing mesenchymal stem/progenitor cells phenocopies the enhanced PTH-induced trabecular bone increase seen in global Nmp4-null mice. Conditional deletion in mature osteoblasts (BglapCre) failed to increase bone volume or PTH response. Conditional disabling in osteocytes (Dmp1Cre) increased BV/TV without boosting PTH response, defining Prx1-expressing MSPCs as the key cell type for Nmp4-mediated suppression of bone anabolism.","method":"Conditional knockout mice (Prx1Cre, BglapCre, Dmp1Cre × Nmp4-floxed), PTH treatment, microCT, histomorphometry, DEXA","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — three independent conditional knockout models tested in parallel with PTH challenge; rigorous cell-type-specific attribution of function","pmids":["36321253"],"is_preprint":false},{"year":2024,"finding":"EP300-ZNF384 fusion protein transactivates the IL3RA (CD123) promoter by directly binding an A-rich sequence at -222/-234 of the IL3RA promoter, as confirmed by ChIP and luciferase reporter assays. EP300-ZNF384-positive B-ALL cells show elevated membrane CD123 and IL-3-stimulated STAT5 activation; knockdown of IL3RA impaired leukemia cell proliferation in vitro and in vivo.","method":"ChIP, luciferase reporter assay, shRNA knockdown of IL3RA, in vitro proliferation assay, in vivo xenograft, STAT5 phosphorylation (Western blot)","journal":"Cell communication and signaling","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP confirms direct promoter binding; luciferase validates transactivation; functional in vitro and in vivo knockdown; multiple orthogonal methods","pmids":["38566191"],"is_preprint":false},{"year":2024,"finding":"RGS1 and CREB5 are identified as direct and common transcriptional target genes of ZNF384 fusion proteins across multiple fusion types. ChIP-qPCR confirmed binding of ZNF384 fusion proteins to regulatory regions of RGS1 and CREB5. ZNF384 fusion-expressing transfectants showed impaired migration toward CXCL12, consistent with RGS1 (an inhibitor of CXCL12-CXCR4 signaling) being upregulated.","method":"RNA-seq of transfectants and clinical ALL samples, ChIP-qPCR, CXCL12 migration assay","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR with RNA-seq cross-validation across multiple fusion types and clinical samples; functional migration assay, single lab","pmids":["39015025"],"is_preprint":false},{"year":2025,"finding":"ZNF384 (ZNF384) was identified as a regulator of the leukemia epigenome. ChIP-seq data show ZNF384 associates with promoters and enhancers in K562 and GM12878 cells, facilitating increased transcription. ZNF384 is enriched at topologically associating domain (TAD) boundaries and chromatin loops (from Hi-C data). ZNF384 shows significant binding at SINE-Alu elements. CRISPRi knockdown of ZNF384 in K562 cells validated transcriptional regulation.","method":"ChIP-seq, RNA-seq, Hi-C chromatin conformation data, CRISPRi knockdown","journal":"Leukemia research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq genome-wide data with Hi-C and CRISPRi knockdown validation, single study; bioinformatic analysis but validated with functional knockdown","pmids":["40250193"],"is_preprint":false},{"year":2025,"finding":"TCF3::ZNF384 (but not EP300::ZNF384) fusion protein expression in BCP-ALL cell lines confers resistance to dexamethasone-induced apoptosis and significantly upregulates CCND2 (cyclin D2) expression, as shown by oligonucleotide microarray and RT-qPCR. Both fusion proteins downregulate CD10 surface expression. These effects are fusion-partner-dependent.","method":"Retrovirus-mediated transduction of BCP-ALL cell lines, annexin-V apoptosis assay, flow cytometry (CD10), oligonucleotide microarray, RT-qPCR","journal":"Pediatrics international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional overexpression in cell lines with apoptosis and gene expression readouts; two fusion types compared; single lab","pmids":["40391410"],"is_preprint":false},{"year":2025,"finding":"ZNF384 functions as a transcriptional activator of SESN2, as confirmed by ChIP and luciferase reporter assays. In LPS-stimulated lung epithelial cells (BEAS-2B), ZNF384 overexpression reduces ferroptosis and inflammation by activating SESN2-mediated autophagy. Depletion of SESN2 reversed these protective effects.","method":"ChIP, luciferase reporter assay, overexpression, siRNA knockdown, ferroptosis markers (MDA, GSH, ROS, Fe2+), ELISA for cytokines","journal":"Toxicology in vitro","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay confirm direct binding; functional rescue experiment with SESN2 depletion validates the pathway; single lab","pmids":["40374019"],"is_preprint":false},{"year":2026,"finding":"ZNF384 acts as a transcriptional activator of Fibulin-1 (Fbln1) in vascular smooth muscle cells, as identified by DNA pull-down assay and dual-luciferase reporter assay. ZNF384-driven Fbln1 promotes VSMC senescence and collagen deposition through the TGF-β/Smad3 pathway. Fbln1 knockdown ameliorates vascular stiffness in aging and Ang II-infusion mouse models.","method":"DNA pull-down assay, dual-luciferase reporter assay, RNA-seq, Fbln1 knockout mouse, Ang II infusion model, pulse wave velocity, histology","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DNA pull-down and reporter assay for direct binding; in vivo mouse models; single lab","pmids":["41816936"],"is_preprint":false}],"current_model":"ZNF384 (also known as CIZ/NMP4) is a C2H2-type zinc finger transcription factor that uses zinc fingers 2, 3, and 6 to bind homopolymeric (dA:dT) DNA sequences in the minor groove, thereby regulating transcription of target genes including MMP-1, MMP-3, MMP-7, MMP-13, COL1A1, IL3RA, FLT3, RGS1, CREB5, SESN2, and Fibulin-1; it nucleocytoplasmically shuttles and localizes to focal adhesions and nuclear matrix subdomains (via its zinc finger domain), interacts with p130(Cas) in rat and zyxin in human cells, and in the context of DNA repair acts as a 'Ku-adaptor' by binding DNA ends via its C2H2 motifs and recruiting Ku70/Ku80 through its N-terminus to promote classical non-homologous end-joining; oncogenic fusions of ZNF384 with transcriptional activators (e.g., EP300, TCF3, EWSR1, TAF15) increase EP300 co-activator binding affinity and transcriptional activity on hematopoietic stem cell gene programs, directly activate an intergenic FLT3 enhancer, and drive lineage-ambiguous leukemia by occupying and deregulating enhancers at key hematopoietic regulators."},"narrative":{"mechanistic_narrative":"ZNF384 (CIZ/NMP4) is a C2H2 zinc finger transcription factor that recognizes homopolymeric (dA:dT) DNA elements through zinc fingers 2, 3, and 6 binding in the minor groove, and which integrates extracellular and mechanical signals into transcriptional programs governing matrix remodeling, bone anabolism, and inflammation [PMID:10669742, PMID:11867614]. It was first identified through its interaction with the SH3 domain of p130(Cas) at focal adhesions, shuttles between cytoplasm and nucleus, and targets its zinc finger domain to nuclear matrix subdomains [PMID:10669742, PMID:10972987]; in human cells the p130(Cas) link is indirect, mediated through zyxin [PMID:16510139]. Depending on promoter context it can activate (MMP-1/3/7, MMP-13, RANKL, IL-1β, AQP5) or repress (COL1A1) transcription, with its N-terminal transactivation potential masked in the full-length protein and unmasked allosterically upon DNA binding [PMID:11149472, PMID:11867614, PMID:15026307, PMID:22307584, PMID:26378628, PMID:27058007]. Across multiple knockout models ZNF384 acts as a brake on bone formation, suppressing BMP-2- and PTH-induced osteoblast anabolism specifically within Prx1-expressing mesenchymal stem/progenitor cells, in part by restraining mechanically induced β-catenin signaling and glycolytic conversion [PMID:15781586, PMID:19189321, PMID:20112285, PMID:30645175, PMID:36321253]. Genome-wide it occupies promoters, enhancers, TAD boundaries, and SINE-Alu elements to regulate transcription [PMID:40250193], and it directly drives pro-inflammatory chemokine/cytokine programs during influenza infection [PMID:32152414]. Independently of transcription, ZNF384 functions as a 'Ku-adaptor' in DNA double-strand break repair: after PARP1-dependent chromatin expansion it binds exposed DNA ends through its C2H2 motifs and recruits Ku70/Ku80 via its N-terminus to promote classical non-homologous end-joining [PMID:34772923]. Recurrent oncogenic fusions of ZNF384 with transcriptional coactivators (EP300, TCF3, EWSR1, TAF15, SYNRG) transform cells via the zinc finger DNA-binding module, bind EP300 with increased affinity, and deregulate hematopoietic stem cell programs and enhancers — directly activating an intergenic FLT3 enhancer and the IL3RA/CD123 promoter — to drive lineage-ambiguous B/myeloid leukemia [PMID:15669012, PMID:31234226, PMID:35247902, PMID:36104354, PMID:38566191].","teleology":[{"year":2000,"claim":"Established ZNF384 as a sequence-specific DNA-binding protein that couples focal adhesion signaling to transcription, answering what kind of molecule it is and what it does.","evidence":"Far-Western screen against p130(Cas) SH3, CAST/SELEX, heterokaryon shuttling assay, and promoter-reporter assays for MMP-1/3/7","pmids":["10669742"],"confidence":"High","gaps":["Direct vs. indirect nature of the p130(Cas) interaction not resolved in human cells","No structural basis for DNA recognition"]},{"year":2000,"claim":"Mapped the determinant of nuclear localization, showing the zinc finger domain is necessary and sufficient for nuclear import and matrix targeting.","evidence":"GFP-fusion immunofluorescence with domain deletions in osteoblasts","pmids":["10972987"],"confidence":"Medium","gaps":["Import receptors/NLS sequence not identified","Functional consequence of matrix subdomain targeting unclear"]},{"year":2001,"claim":"Showed ZNF384 can act as a transcriptional repressor as well as activator, establishing context-dependent regulation of COL1A1 via poly(dT) binding and DNA bending.","evidence":"Expression-library screening, promoter mutagenesis, antibody disruption and overexpression in UMR-106 osteoblasts","pmids":["11149472"],"confidence":"High","gaps":["Determinants that switch ZNF384 between activation and repression not defined"]},{"year":2002,"claim":"Defined the molecular logic of DNA recognition and activation — fingers 2/3/6 bind the minor groove and DNA binding allosterically unmasks the otherwise repressed N-terminal/poly(QA) transactivation function.","evidence":"GAL4 fusion transactivation, zinc-finger deletion mutagenesis, in vitro DNA binding and reporter assays","pmids":["11867614"],"confidence":"High","gaps":["Structural model of the allosteric activation not available","Cofactors recruited by the unmasked activation domain unknown"]},{"year":2002,"claim":"First linked ZNF384 to leukemia via EWSR1 and TAF15 fusions, showing they transform cells independently of normal target-gene regulation.","evidence":"RT-PCR cloning of fusion transcripts and NIH3T3 focus formation with target gene expression analysis","pmids":["12359745"],"confidence":"Medium","gaps":["Mechanism of transformation not yet linked to specific target genes","Single transformation assay system"]},{"year":2005,"claim":"Established ZNF384 as a physiological suppressor of bone mass acting through inhibition of BMP signaling, defining its in vivo role.","evidence":"CIZ-knockout mouse histomorphometry, BMP-2 calvarial injection, and bone marrow differentiation assays","pmids":["15781586"],"confidence":"High","gaps":["Direct molecular target in the BMP/Smad pathway not defined","Whether suppression is transcriptional or via protein interaction unresolved"]},{"year":2005,"claim":"Showed the zinc fingers are obligatory for the oncogenic activity of fusions, demonstrating transformation requires ZNF384 DNA binding.","evidence":"Domain-deletion mutagenesis with NIH3T3 focus formation and MMP7 luciferase reporter for TCF3/VP16 fusions","pmids":["15669012"],"confidence":"High","gaps":["Endogenous target genes driving transformation not identified at this stage"]},{"year":2006,"claim":"Revised the interactome for human ZNF384, finding zyxin (not direct p130CAS), PCBP1, and vimentin as partners.","evidence":"Yeast two-hybrid screening in human cells","pmids":["16510139"],"confidence":"Low","gaps":["Yeast two-hybrid only with no orthogonal validation of the interactions","Functional consequence of zyxin/PCBP1/vimentin binding untested"]},{"year":2010,"claim":"Connected ZNF384 to mechanotransduction, showing it restrains mechanically induced β-catenin and growth-factor signaling in osteoblasts.","evidence":"Nmp4-null osteoblasts under oscillatory fluid shear stress with fractionation, Western blot, and immunofluorescence (also EMSA-based MMP-13 mechanoregulation [#12], unloading models [#13])","pmids":["20112285","17455210","17301008"],"confidence":"Medium","gaps":["Direct mechanism linking ZNF384 to β-catenin nuclear entry unknown","Upstream mechanosensor coupling to ZNF384 undefined"]},{"year":2015,"claim":"Extended ZNF384 function to inflammation and innate immunity, showing direct activation of pro-inflammatory and chemokine gene programs.","evidence":"ChIP and knockout-mouse phenotyping in K/BxN arthritis and influenza infection models with cytokine/chemokine readouts","pmids":["26378628","32152414"],"confidence":"High","gaps":["Signals that activate ZNF384 inflammatory targets in vivo not defined","Cell-type-specific contributions partially resolved"]},{"year":2019,"claim":"Defined cell-type-specific and metabolic mechanisms of bone suppression, localizing ZNF384 function to Prx1+ MSPCs and linking it to glycolysis and collagen output.","evidence":"Conditional knockout mice (Prx1/Bglap/Dmp1 Cre), RNA-seq, metabolic and biomechanical assays with PTH challenge","pmids":["36321253","30645175","19189321","26244796"],"confidence":"High","gaps":["Direct transcriptional targets governing glycolytic switch not pinpointed","Mechanism of PTH-response modulation unresolved"]},{"year":2019,"claim":"Mechanistically explained why fusion oncoproteins are more potent — they bind the EP300 coactivator with increased affinity and hyperactivate target promoters/enhancers.","evidence":"GST pull-down and enhancer/promoter reporter assays for EP300- and SYNRG-ZNF384 fusions","pmids":["31234226"],"confidence":"Medium","gaps":["Genome-wide chromatin consequences not yet mapped at this stage"]},{"year":2021,"claim":"Revealed a transcription-independent role in DNA repair, defining ZNF384 as a Ku-adaptor that bridges DNA ends to the NHEJ machinery.","evidence":"In vitro DNA-end binding, laser microirradiation recruitment, PARP1 inhibition, Co-IP with Ku70/Ku80, domain mapping and NHEJ reporter","pmids":["34772923"],"confidence":"High","gaps":["How transcriptional and repair functions are coordinated/partitioned unknown","Whether repair role is altered in fusion-bearing leukemia not tested"]},{"year":2022,"claim":"Established the genome-wide oncogenic mechanism: fusion proteins occupy enhancers, increase H3K27ac, deregulate HSC transcription factors, and directly activate a FLT3 enhancer to drive lineage-ambiguous leukemia.","evidence":"ChIP-seq, chromatin conformation capture, viral expression and Ep300::Znf384 knockin mouse, xenografts with FLT3 inhibitor treatment","pmids":["35247902","36104354"],"confidence":"High","gaps":["Full target-gene network across fusion types not exhaustively defined","Determinants of B vs myeloid lineage skewing incomplete"]},{"year":2024,"claim":"Identified additional direct fusion target genes (IL3RA/CD123, RGS1, CREB5) that confer therapeutically actionable and migration phenotypes.","evidence":"ChIP/ChIP-qPCR, luciferase reporters, shRNA knockdown, STAT5 signaling, migration assays and xenografts across multiple fusion types","pmids":["38566191","39015025"],"confidence":"Medium","gaps":["Relative contribution of each target to leukemogenesis not ranked","RGS1/CREB5 functional validation limited to migration assays"]},{"year":2025,"claim":"Showed fusion-partner identity dictates distinct downstream phenotypes (e.g., TCF3 fusion-specific dexamethasone resistance and CCND2 upregulation).","evidence":"Retroviral transduction of BCP-ALL lines, apoptosis assays, flow cytometry, microarray and RT-qPCR; plus genome-wide CRISPRi/ChIP-seq/Hi-C epigenome mapping","pmids":["40391410","40250193"],"confidence":"Medium","gaps":["Molecular basis of partner-specific differences not defined","Generalizability of K562/GM12878 epigenome findings to leukemia subtypes unclear"]},{"year":2025,"claim":"Expanded the cytoprotective/disease repertoire, showing ZNF384 activates SESN2-mediated autophagy and Fibulin-1-driven vascular pathways.","evidence":"ChIP/DNA pull-down, luciferase reporters, rescue experiments, ferroptosis markers, and in vivo vascular stiffness models","pmids":["40374019","41816936"],"confidence":"Medium","gaps":["Conditions activating these programs physiologically unclear","Single-lab findings without independent replication"]},{"year":null,"claim":"How ZNF384 selects between transcriptional activation, repression, and DNA-end repair functions — and how fusion partners reprogram its genomic targeting — remains mechanistically unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of DNA recognition or coactivator engagement","Coordination between repair and transcription roles unknown","Determinants of activation-vs-repression switching undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,4,6,20,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,4,17,18,23,29]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,4,23,25]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[25,26,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[23,18]}],"complexes":[],"partners":["P130CAS (BCAR1)","ZYXIN (ZYX)","PCBP1","VIMENTIN (VIM)","EP300","KU70 (XRCC6)","KU80 (XRCC5)","COL1A1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TF68","full_name":"Zinc finger protein 384","aliases":["CAG repeat protein 1","CAS-interacting zinc finger protein","Nuclear matrix transcription factor 4","Nuclear matrix protein 4","Trinucleotide repeat-containing gene 1 protein"],"length_aa":577,"mass_kda":63.2,"function":"Transcription factor that binds the consensus DNA sequence [GC]AAAAA. Seems to bind and regulate the promoters of MMP1, MMP3, MMP7 and COL1A1 (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8TF68/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF384","classification":"Not Classified","n_dependent_lines":32,"n_total_lines":1208,"dependency_fraction":0.026490066225165563},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"MED9","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZNF384","total_profiled":1310},"omim":[{"mim_id":"609951","title":"ZINC FINGER PROTEIN 384; ZNF384","url":"https://www.omim.org/entry/609951"},{"mim_id":"166710","title":"OSTEOPOROSIS","url":"https://www.omim.org/entry/166710"},{"mim_id":"120150","title":"COLLAGEN, TYPE I, ALPHA-1; COL1A1","url":"https://www.omim.org/entry/120150"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZNF384"},"hgnc":{"alias_symbol":["CAGH1A","CIZ","NMP4","NP"],"prev_symbol":["TNRC1"]},"alphafold":{"accession":"Q8TF68","domains":[{"cath_id":"3.30.160,3.30.160","chopping":"400-459","consensus_level":"medium","plddt":71.7658,"start":400,"end":459}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TF68","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TF68-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TF68-F1-predicted_aligned_error_v6.png","plddt_mean":60.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF384","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF384"},"sequence":{"accession":"Q8TF68","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TF68.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TF68/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TF68"}},"corpus_meta":[{"pmid":"27634205","id":"PMC_27634205","title":"ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.","date":"2016","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/27634205","citation_count":183,"is_preprint":false},{"pmid":"10669742","id":"PMC_10669742","title":"CIZ, a zinc finger protein that interacts with p130(cas) and activates the expression of matrix metalloproteinases.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10669742","citation_count":115,"is_preprint":false},{"pmid":"12359745","id":"PMC_12359745","title":"Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12359745","citation_count":100,"is_preprint":false},{"pmid":"29797659","id":"PMC_29797659","title":"Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.","date":"2018","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29797659","citation_count":81,"is_preprint":false},{"pmid":"15781586","id":"PMC_15781586","title":"The nucleocytoplasmic shuttling protein CIZ reduces adult bone mass by inhibiting bone morphogenetic protein-induced bone formation.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15781586","citation_count":58,"is_preprint":false},{"pmid":"11149472","id":"PMC_11149472","title":"Cloning and functional analysis of a family of nuclear matrix transcription factors (NP/NMP4) that regulate type I collagen expression in osteoblasts.","date":"2001","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/11149472","citation_count":58,"is_preprint":false},{"pmid":"27392123","id":"PMC_27392123","title":"Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.","date":"2016","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27392123","citation_count":54,"is_preprint":false},{"pmid":"34772923","id":"PMC_34772923","title":"Zinc finger protein ZNF384 is an adaptor of Ku to DNA during classical non-homologous end-joining.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34772923","citation_count":41,"is_preprint":false},{"pmid":"15026307","id":"PMC_15026307","title":"Nmp4/CIZ regulation of matrix metalloproteinase 13 (MMP-13) response to parathyroid hormone in osteoblasts.","date":"2004","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15026307","citation_count":36,"is_preprint":false},{"pmid":"18185522","id":"PMC_18185522","title":"E2A-ZNF384 and NOL1-E2A fusion created by a cryptic t(12;19)(p13.3; p13.3) in acute leukemia.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18185522","citation_count":33,"is_preprint":false},{"pmid":"15189450","id":"PMC_15189450","title":"Impaired spermatogenesis and male fertility defects in CIZ/Nmp4-disrupted mice.","date":"2004","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/15189450","citation_count":30,"is_preprint":false},{"pmid":"16510139","id":"PMC_16510139","title":"Interaction partners for human ZNF384/CIZ/NMP4--zyxin as a mediator for p130CAS signaling?","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16510139","citation_count":29,"is_preprint":false},{"pmid":"21504714","id":"PMC_21504714","title":"Identification of the TAF15-ZNF384 fusion gene in two new cases of acute lymphoblastic leukemia with a t(12;17)(p13;q12).","date":"2011","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21504714","citation_count":29,"is_preprint":false},{"pmid":"35669784","id":"PMC_35669784","title":"ZNF384: A Potential Therapeutic Target for Psoriasis and Alzheimer's Disease Through Inflammation and Metabolism.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35669784","citation_count":28,"is_preprint":false},{"pmid":"19189321","id":"PMC_19189321","title":"Nmp4/CIZ suppresses parathyroid hormone-induced increases in trabecular bone.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19189321","citation_count":28,"is_preprint":false},{"pmid":"35247902","id":"PMC_35247902","title":"ZNF384 Fusion Oncoproteins Drive Lineage Aberrancy in Acute Leukemia.","date":"2022","source":"Blood cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35247902","citation_count":27,"is_preprint":false},{"pmid":"12067068","id":"PMC_12067068","title":"Involvement of the nuclear matrix in the control of skeletal genes: the NMP1 (YY1), NMP2 (Cbfa1), and NMP4 (Nmp4/CIZ) transcription factors.","date":"2001","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/12067068","citation_count":27,"is_preprint":false},{"pmid":"11867614","id":"PMC_11867614","title":"DNA binding and gene activation properties of the Nmp4 nuclear matrix transcription factors.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11867614","citation_count":26,"is_preprint":false},{"pmid":"10972987","id":"PMC_10972987","title":"NP/NMP4 transcription factors have distinct osteoblast nuclear matrix subdomains.","date":"2000","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10972987","citation_count":24,"is_preprint":false},{"pmid":"36104354","id":"PMC_36104354","title":"Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36104354","citation_count":20,"is_preprint":false},{"pmid":"11112339","id":"PMC_11112339","title":"Overexpression of Cas-interacting zinc finger protein (CIZ) suppresses proliferation and enhances expression of type I collagen gene in osteoblast-like MC3T3E1 cells.","date":"2000","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11112339","citation_count":20,"is_preprint":false},{"pmid":"37306722","id":"PMC_37306722","title":"ZNF384-Related Fusion Genes in Acute Lymphoblastic Leukemia.","date":"2023","source":"Cancer control : journal of the Moffitt Cancer Center","url":"https://pubmed.ncbi.nlm.nih.gov/37306722","citation_count":19,"is_preprint":false},{"pmid":"34529760","id":"PMC_34529760","title":"A novel class of ZNF384 aberrations in acute leukemia.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34529760","citation_count":19,"is_preprint":false},{"pmid":"17455210","id":"PMC_17455210","title":"Nmp4/CIZ contributes to fluid shear stress induced MMP-13 gene induction in osteoblasts.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17455210","citation_count":19,"is_preprint":false},{"pmid":"36100877","id":"PMC_36100877","title":"ZNF384-ZEB1 feedback loop regulates breast cancer metastasis.","date":"2022","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/36100877","citation_count":18,"is_preprint":false},{"pmid":"20112285","id":"PMC_20112285","title":"Nmp4/CIZ inhibits mechanically induced beta-catenin signaling activity in osteoblasts.","date":"2010","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20112285","citation_count":18,"is_preprint":false},{"pmid":"17301008","id":"PMC_17301008","title":"Deficiency of CIZ, a nucleocytoplasmic shuttling protein, prevents unloading-induced bone loss through the enhancement of osteoblastic bone formation in vivo.","date":"2007","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/17301008","citation_count":18,"is_preprint":false},{"pmid":"30645175","id":"PMC_30645175","title":"Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality.","date":"2019","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30645175","citation_count":17,"is_preprint":false},{"pmid":"22873745","id":"PMC_22873745","title":"Nmp4/CIZ suppresses the parathyroid hormone anabolic window by restricting mesenchymal stem cell and osteoprogenitor frequency.","date":"2012","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/22873745","citation_count":17,"is_preprint":false},{"pmid":"21607813","id":"PMC_21607813","title":"Nmp4/CIZ suppresses the response of bone to anabolic parathyroid hormone by regulating both osteoblasts and osteoclasts.","date":"2011","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/21607813","citation_count":17,"is_preprint":false},{"pmid":"21732358","id":"PMC_21732358","title":"Immortalization and characterization of osteoblast cell lines generated from wild-type and Nmp4-null mouse bone marrow stromal cells using murine telomerase reverse transcriptase (mTERT).","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21732358","citation_count":15,"is_preprint":false},{"pmid":"26244796","id":"PMC_26244796","title":"Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis.","date":"2015","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26244796","citation_count":14,"is_preprint":false},{"pmid":"31234226","id":"PMC_31234226","title":"ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.","date":"2019","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/31234226","citation_count":14,"is_preprint":false},{"pmid":"19766748","id":"PMC_19766748","title":"Nmp4/CIZ: road block at the intersection of PTH and load.","date":"2009","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/19766748","citation_count":13,"is_preprint":false},{"pmid":"36321253","id":"PMC_36321253","title":"Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells Enhances PTH-Induced Bone Formation.","date":"2022","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/36321253","citation_count":12,"is_preprint":false},{"pmid":"26378628","id":"PMC_26378628","title":"Mice Deficient in CIZ/NMP4 Develop an Attenuated Form of K/BxN-Serum Induced Arthritis.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26378628","citation_count":12,"is_preprint":false},{"pmid":"15669012","id":"PMC_15669012","title":"Cellular transformation of NIH3T3 fibroblasts by CIZ/NMP4 fusions.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15669012","citation_count":12,"is_preprint":false},{"pmid":"32152414","id":"PMC_32152414","title":"NMP4 regulates the innate immune response to influenza A virus infection.","date":"2020","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32152414","citation_count":11,"is_preprint":false},{"pmid":"27607436","id":"PMC_27607436","title":"Mixed Phenotype Acute Leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and Other Chromosome Abnormalities.","date":"2016","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/27607436","citation_count":10,"is_preprint":false},{"pmid":"32980888","id":"PMC_32980888","title":"Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.","date":"2020","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/32980888","citation_count":10,"is_preprint":false},{"pmid":"26293203","id":"PMC_26293203","title":"Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion.","date":"2015","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26293203","citation_count":10,"is_preprint":false},{"pmid":"34395283","id":"PMC_34395283","title":"Leukemia With TCF3-ZNF384 Rearrangement as a Distinct Subtype of Disease With Distinct Treatments: Perspectives From A Case Report and Literature Review.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34395283","citation_count":10,"is_preprint":false},{"pmid":"15716059","id":"PMC_15716059","title":"Two promoters control the mouse Nmp4/CIZ transcription factor gene.","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/15716059","citation_count":9,"is_preprint":false},{"pmid":"22307584","id":"PMC_22307584","title":"CIZ/NMP4 is expressed in B16 melanoma and forms a positive feedback loop with RANKL to promote migration of the melanoma cells.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22307584","citation_count":9,"is_preprint":false},{"pmid":"35921545","id":"PMC_35921545","title":"Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.","date":"2022","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/35921545","citation_count":9,"is_preprint":false},{"pmid":"30150451","id":"PMC_30150451","title":"An Adult Patient with Early Pre-B Acute Lymphoblastic Leukemia with t(12;17)(p13;q21)/ZNF384-TAF15.","date":"2018","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/30150451","citation_count":8,"is_preprint":false},{"pmid":"33988307","id":"PMC_33988307","title":"Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.","date":"2021","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33988307","citation_count":8,"is_preprint":false},{"pmid":"38566191","id":"PMC_38566191","title":"EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38566191","citation_count":7,"is_preprint":false},{"pmid":"38141017","id":"PMC_38141017","title":"A Transcription Factor ZNF384, Regulated by LINC00265, Activates the Expression of IFI30 to Stimulate Malignant Progression in Glioma.","date":"2023","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38141017","citation_count":7,"is_preprint":false},{"pmid":"27058007","id":"PMC_27058007","title":"The Transcription Factor NMP4 Binds to the AQP5 Promoter and Is a Novel Transcriptional Regulator of the AQP5 Gene.","date":"2016","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27058007","citation_count":7,"is_preprint":false},{"pmid":"12052465","id":"PMC_12052465","title":"Osteoblast intracellular localization of Nmp4 proteins.","date":"2002","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/12052465","citation_count":7,"is_preprint":false},{"pmid":"18211825","id":"PMC_18211825","title":"Ciz, a transcription factor with a nucleocytoplasmic shuttling activity, interacts with C-propeptides of type I collagen.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18211825","citation_count":6,"is_preprint":false},{"pmid":"23140162","id":"PMC_23140162","title":"Nmp4/CIZ closes the parathyroid hormone anabolic window.","date":"2012","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/23140162","citation_count":5,"is_preprint":false},{"pmid":"37660938","id":"PMC_37660938","title":"Loss of Nmp4 enhances bone gain from sclerostin antibody administration.","date":"2023","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/37660938","citation_count":5,"is_preprint":false},{"pmid":"34417862","id":"PMC_34417862","title":"Nmp4, a Regulator of Induced Osteoanabolism, Also Influences Insulin Secretion and Sensitivity.","date":"2021","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/34417862","citation_count":5,"is_preprint":false},{"pmid":"39562372","id":"PMC_39562372","title":"The pivotal role of ZNF384: driving the malignant behavior of serous ovarian cancer cells via the LIN28B/UBD axis.","date":"2024","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/39562372","citation_count":5,"is_preprint":false},{"pmid":"39342516","id":"PMC_39342516","title":"METTL3-mediated m6A modification of ZNF384 promotes hepatocellular carcinoma progression by transcriptionally activating ACSM1.","date":"2024","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/39342516","citation_count":5,"is_preprint":false},{"pmid":"37147466","id":"PMC_37147466","title":"NMP4, an Arbiter of Bone Cell Secretory Capacity and Regulator of Skeletal Response to PTH Therapy.","date":"2023","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/37147466","citation_count":4,"is_preprint":false},{"pmid":"35735203","id":"PMC_35735203","title":"Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR-ABL1, KMT2A rearrangement, and other adult B-cell precursor acute lymphoblastic leukemia.","date":"2022","source":"Cytometry. Part B, Clinical cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/35735203","citation_count":4,"is_preprint":false},{"pmid":"19426707","id":"PMC_19426707","title":"TAF15 and the leukemia-associated fusion protein TAF15-CIZ/NMP4 are cleaved by caspases-3 and -7.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19426707","citation_count":4,"is_preprint":false},{"pmid":"38287528","id":"PMC_38287528","title":"ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.","date":"2024","source":"Hematological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38287528","citation_count":4,"is_preprint":false},{"pmid":"26423071","id":"PMC_26423071","title":"Low BIK outside-inside-out interactive inflammation immune-induced transcription-dependent apoptosis through FUT3-PMM2-SQSTM1-SFN-ZNF384.","date":"2016","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/26423071","citation_count":4,"is_preprint":false},{"pmid":"38824270","id":"PMC_38824270","title":"ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis.","date":"2024","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38824270","citation_count":3,"is_preprint":false},{"pmid":"33145596","id":"PMC_33145596","title":"Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia.","date":"2021","source":"Laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33145596","citation_count":3,"is_preprint":false},{"pmid":"36052266","id":"PMC_36052266","title":"Whole transcriptome sequencing reveals a TCF4-ZNF384 fusion in acute lymphoblastic leukemia.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36052266","citation_count":3,"is_preprint":false},{"pmid":"40453923","id":"PMC_40453923","title":"ZNF384 mediates KRT23 to promote CRC process through the TGF-β/Smad signaling pathway.","date":"2025","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/40453923","citation_count":3,"is_preprint":false},{"pmid":"34744437","id":"PMC_34744437","title":"MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34744437","citation_count":3,"is_preprint":false},{"pmid":"40250193","id":"PMC_40250193","title":"Identification of ZNF384 as a regulator of epigenome in leukemia.","date":"2025","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/40250193","citation_count":2,"is_preprint":false},{"pmid":"39015025","id":"PMC_39015025","title":"RGS1 and CREB5 are direct and common transcriptional targets of ZNF384-fusion proteins.","date":"2024","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39015025","citation_count":2,"is_preprint":false},{"pmid":"40391410","id":"PMC_40391410","title":"TCF3::ZNF384 induces steroid resistance in B-cell precursor acute lymphoblastic leukemia cells.","date":"2025","source":"Pediatrics international : official journal of the Japan Pediatric Society","url":"https://pubmed.ncbi.nlm.nih.gov/40391410","citation_count":1,"is_preprint":false},{"pmid":"39469177","id":"PMC_39469177","title":"Clinicopathological and Immunophenotypic Characteristics of Series of ZNF384 Re-arranged Acute Leukemias.","date":"2024","source":"Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/39469177","citation_count":1,"is_preprint":false},{"pmid":"32027248","id":"PMC_32027248","title":"[Analysis of Clinical Characteristics of Acute B Lymphoblastic Leukemia with EP300-ZNF384 Fusion Gene Positive].","date":"2020","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/32027248","citation_count":1,"is_preprint":false},{"pmid":"39531055","id":"PMC_39531055","title":"Mixed-phenotype leukemia with TCF3::ZNF384 fusion presenting as an isolated mediastinal mass.","date":"2024","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/39531055","citation_count":1,"is_preprint":false},{"pmid":"41158816","id":"PMC_41158816","title":"TAF15::ZNF384 Mixed Phenotype Acute Leukemia With Complex Karyotype: Case Report With B-ALL Induction, Blinatumomab Bridging to Allogeneic Transplant and Literature Review.","date":"2025","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41158816","citation_count":1,"is_preprint":false},{"pmid":"41553436","id":"PMC_41553436","title":"ZNF384-regulated SLC31A1 expression promotes tumor proliferation and invasion in breast cancer.","date":"2026","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41553436","citation_count":0,"is_preprint":false},{"pmid":"41429980","id":"PMC_41429980","title":"Unveiling the ZNF384-INTS13-hnRNPC axis as a therapeutic vulnerability in cervical cancer.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41429980","citation_count":0,"is_preprint":false},{"pmid":"41816936","id":"PMC_41816936","title":"ZNF384-Driven Fibulin-1 Exacerbates Vascular Stiffness via TGF-β/Smad3-Mediated Senescence and Fibrosis.","date":"2026","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41816936","citation_count":0,"is_preprint":false},{"pmid":"37544723","id":"PMC_37544723","title":"[Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].","date":"2023","source":"[Rinsho ketsueki] The Japanese journal of clinical hematology","url":"https://pubmed.ncbi.nlm.nih.gov/37544723","citation_count":0,"is_preprint":false},{"pmid":"40374019","id":"PMC_40374019","title":"Zinc finger transcription factor ZNF384 mitigates LPS-induced ferroptosis and inflammation in lung epithelial cells by activating SESN2-mediated autophagy.","date":"2025","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/40374019","citation_count":0,"is_preprint":false},{"pmid":"39961407","id":"PMC_39961407","title":"ZNF384 and m6A methylation promote the progression of hepatocellular carcinoma by regulating the interaction between LINC00342 and DAPK1.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/39961407","citation_count":0,"is_preprint":false},{"pmid":"33834463","id":"PMC_33834463","title":"[Identification of TCF3-ZNF384 fusion by transcriptome sequencing in B cell acute lymphoblastic leukemia and its laboratory and clinical characteristics].","date":"2021","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33834463","citation_count":0,"is_preprint":false},{"pmid":"40873094","id":"PMC_40873094","title":"[Clinical features of acute B lymphoblastic leukemia with TAF15::ZNF384 fusion gene].","date":"2025","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/40873094","citation_count":0,"is_preprint":false},{"pmid":"39520726","id":"PMC_39520726","title":"FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.","date":"2024","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/39520726","citation_count":0,"is_preprint":false},{"pmid":"41565170","id":"PMC_41565170","title":"Improvements in bone quality by parathyroid hormone treatment are enhanced in the Nmp4 knockout mouse model.","date":"2026","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/41565170","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44528,"output_tokens":9521,"usd":0.1382,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19796,"output_tokens":5393,"usd":0.116903,"stage2_stop_reason":"end_turn"},"total_usd":0.255103,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"CIZ (ZNF384) was identified as a novel protein that binds the SH3 domain of p130(Cas) via far-Western screening. CIZ co-localizes at focal adhesions and in the nucleus, and acts as a nucleocytoplasmic shuttling protein (demonstrated by transient interspecies heterokaryon formation assay). CIZ binds DNA with consensus sequence (G/C)AAAAA(A) as determined by cyclic amplification and selection of targets (CAST) analysis, and specifically binds the MMP-1 promoter. Overexpression of CIZ upregulates transcription from MMP-1, MMP-3, and MMP-7 promoters, with transactivation enhanced in the presence of Cas.\",\n      \"method\": \"Far-Western screening, heterokaryon shuttling assay, CAST/SELEX DNA binding consensus, promoter-reporter assays, co-immunoprecipitation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (far-Western, CAST, heterokaryon assay, promoter-reporter, Co-IP) in a single foundational study; founding paper for the protein\",\n      \"pmids\": [\"10669742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"NP/NMP4 (ZNF384) proteins localize to distinct nuclear matrix subdomains in osteoblasts. The zinc finger domain was shown to be both necessary and sufficient for nuclear import and nuclear matrix targeting, as determined by immunofluorescence of GFP-NP/NMP4 fusion proteins.\",\n      \"method\": \"Immunofluorescence microscopy, GFP fusion protein localization, domain deletion analysis\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization with domain mapping using multiple constructs, single lab\",\n      \"pmids\": [\"10972987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NP/NMP4/CIZ (ZNF384) binds to poly(dT) sequences (sites A and B) in the rat type I collagen alpha1(I) (COL1A1) promoter and bends the DNA. Mutation of sites A or B increased COL1A1 promoter activity in UMR-106 osteoblast-like cells. Overexpression of specific NMP4 clones repressed COL1A1 promoter activity, demonstrating that NMP4/CIZ functions as a transcriptional repressor of COL1A1.\",\n      \"method\": \"Expression library screening with site B probe, promoter-reporter constructs with site mutations, antibody disruption of DNA-protein complexes, overexpression assays\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (DNA binding, antibody disruption, promoter mutagenesis, overexpression in osteoblasts), single lab but comprehensive mechanistic dissection\",\n      \"pmids\": [\"11149472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Overexpression of CIZ (ZNF384) in MC3T3E1 osteoblast-like cells increased focal adhesion plaque number, reduced cell proliferation, enhanced type I collagen mRNA expression, and upregulated a heterologous promoter driven by a CIZ-consensus binding sequence within the type I collagen gene promoter.\",\n      \"method\": \"Overexpression, promoter-reporter assay, RT-PCR, immunofluorescence\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — promoter binding confirmed, multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"11112339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Zinc fingers 2, 3, and 6 of Nmp4 mediate binding to the homopolymeric (dA.dT) COL1A1/MMP DNA consensus element (minor groove binding). The N-terminus has strong transactivation capacity when fused to GAL4 DBD, but this activity is masked in the full-length protein. Upon binding to the homopolymeric (dA.dT) element, native Nmp4 upregulates transcription, and the polyglutamine-alanine (poly(QA)) domain acquires a significant transactivation role, suggesting allosteric activation by DNA binding.\",\n      \"method\": \"GAL4 fusion transactivation assays, deletion mutagenesis of zinc fingers, promoter-reporter assays, in vitro DNA binding\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro DNA binding combined with domain mutagenesis and reporter assays; mechanistic dissection of activation domains\",\n      \"pmids\": [\"11867614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CIZ/NMP4 (ZNF384) fuses with EWSR1 (via t(12;22)) or TAF15 (via t(12;17)) in acute leukemia. The resulting fusion proteins have transforming properties in NIH3T3 cells (focus formation assay), but do not affect the expression of CIZ target genes (MMP-1, COL1A1), suggesting oncogenic activity independent of normal CIZ transactivation.\",\n      \"method\": \"RT-PCR/cloning of fusion transcripts, NIH3T3 focus formation assay, target gene expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transformation assay plus target gene expression, replicated across two fusion types, single lab\",\n      \"pmids\": [\"12359745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Nmp4/CIZ (ZNF384) binds an electrophoretically confirmed cis-element within the MMP-13 PTH response region (-119/-110 nt homopolymeric dA:dT). Mutation of this element decreases basal MMP-13 promoter activity but enhances its PTH/PGE2 responsiveness. Overexpression of Nmp4/CIZ enhances basal MMP-13 promoter activity but diminishes hormone-induced induction.\",\n      \"method\": \"EMSA (electrophoretic mobility shift assay), promoter-reporter mutagenesis, overexpression assays in osteoblasts\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — EMSA binding combined with promoter mutagenesis and overexpression, multiple orthogonal methods, mechanistically defined role\",\n      \"pmids\": [\"15026307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CIZ/Nmp4 knockout mice show increased spermatogenic cell apoptosis and variable degrees of spermatogenic cell degeneration in seminiferous tubules, resulting in male infertility in some mice. CIZ/Nmp4 co-localizes with Smad1 in the testis, suggesting it modulates BMP signaling in spermatogenesis.\",\n      \"method\": \"Gene knockout (disruption by beta-galactosidase/neomycin insertion in exon 2), histological analysis, TUNEL assay, immunolocalization\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout with specific cellular phenotype (apoptosis by TUNEL) and co-localization with Smad1, single lab\",\n      \"pmids\": [\"15189450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CIZ-deficient mice show increased bone volume and bone formation rates without changes in bone resorption. CIZ deficiency enhances BMP-2-induced osteoblastic differentiation of bone marrow cells, and BMP-2-induced bone formation on calvariae in vivo is enhanced in CIZ-null mice. This establishes that CIZ (ZNF384) suppresses adult bone mass by inhibiting BMP signaling-induced osteoblast activity.\",\n      \"method\": \"CIZ knockout mouse, bone histomorphometry, bone marrow cell cultures (ALP, mineralization), in vivo BMP-2 calvarial injection, mRNA expression analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout with multiple orthogonal in vivo and in vitro assays, replicated across multiple bone formation assays, single lab but comprehensive\",\n      \"pmids\": [\"15781586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"E2A-CIZ (TCF3-ZNF384) and VP16-CIZ fusion proteins transform NIH3T3 fibroblasts in focus formation assays. Deletion of the zinc fingers of CIZ abolished both DNA-binding and transforming properties of TAF15-CIZ, while deletion of other CIZ domains had no effect. E2A-CIZ and VP16-CIZ transactivate the MMP7 promoter in luciferase assays, indicating transformation involves ZNF384 zinc finger-mediated DNA binding and transactivation.\",\n      \"method\": \"NIH3T3 focus formation assay, domain deletion mutagenesis, luciferase reporter assay\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — domain deletion mutagenesis combined with transformation assay and reporter assay; mechanistically defines the required domains\",\n      \"pmids\": [\"15669012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The mouse Nmp4/CIZ gene is driven by two adjacent promoters (P1 and P2) that initiate transcription of alternative first exons. Both promoters lack TATA/CCAAT boxes but contain initiator sites and CpG islands. PTH at low doses attenuates P1/P2 activity in osteoblast-like cells. The promoters are autoregulated, and deletion analysis identified positive and negative regulatory regions.\",\n      \"method\": \"Promoter-reporter assays, Northern blot, deletion analysis, PTH treatment\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter-reporter with deletion analysis and physiological stimulus, single lab\",\n      \"pmids\": [\"15716059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Human ZNF384 does not interact with p130CAS directly (in contrast to rat CIZ). Instead, yeast two-hybrid screening identified zyxin, PCBP1, and vimentin as ZNF384 binding partners in human cells. Zyxin can interact with p130CAS, suggesting that zyxin mediates an indirect interaction between ZNF384 and p130CAS in human cells.\",\n      \"method\": \"Yeast two-hybrid screening\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid only, no orthogonal validation of interactions, single lab\",\n      \"pmids\": [\"16510139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nmp4/CIZ (ZNF384) contributes to fluid shear stress (FSS)-induced MMP-13 transcription. FSS decreased Nmp4/CIZ binding to its cis-element in the MMP-13 PTH response region (measured by EMSA), and mutation of this element abolished FSS-induced MMP-13 promoter activity. FSS also enhanced Nmp4/CIZ promoter activity and induced p130(Cas) nuclear translocation.\",\n      \"method\": \"EMSA, promoter-reporter assay with mutation, fluid shear stress application, RT-qPCR\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and promoter mutagenesis with physiological mechanical stimulus, multiple readouts, single lab\",\n      \"pmids\": [\"17455210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CIZ (ZNF384) deficiency blocks unloading-induced reduction in osteoblastic bone formation parameters in vivo. CIZ-deficient mice resist tail suspension-induced bone loss. Bone marrow cell cultures from unloaded CIZ-null mice maintain mineralized nodule formation, which is suppressed in wild-type unloaded mice, demonstrating CIZ acts in mechanosensory signaling in bone.\",\n      \"method\": \"Tail suspension (unloading) model, bone histomorphometry, bone marrow cell cultures, mineralized nodule formation assay\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse with in vivo and in vitro mechanistic validation, single lab\",\n      \"pmids\": [\"17301008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Yeast two-hybrid screening of Ciz (ZNF384) binding partners revealed that 47% of positive clones encode extracellular matrix proteins, including Col1a1, Col1a2, Fbln2, and Rpsa. In vitro co-immunoprecipitation using in vitro-translated proteins showed direct binding of Ciz-deltaZF (lacking zinc fingers) to C-propeptides of Col1a1 and Col1a2. In vivo co-immunoprecipitation of transfected Ciz and C-propeptide of Col1a1 was confirmed in COS-7 cells. C-propeptides and Ciz co-localize in the nucleus when overexpressed.\",\n      \"method\": \"Yeast two-hybrid, in vitro translation + co-IP, in vivo co-IP (COS-7 cells), co-localization immunofluorescence\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with both in vitro and in vivo systems, single lab\",\n      \"pmids\": [\"18211825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Nmp4/CIZ knockout mice exhibit a significantly greater PTH-induced acquisition of femoral trabecular bone versus wild-type mice, establishing that Nmp4/CIZ suppresses PTH-mediated anabolic bone formation. The baseline phenotype showed modestly elevated bone mineral density in null mice.\",\n      \"method\": \"Nmp4-knockout mouse, PTH treatment, microCT, DEXA, histomorphometry\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with PTH challenge and multiple skeletal readouts, single lab\",\n      \"pmids\": [\"19189321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Nmp4/CIZ (ZNF384) inhibits mechanically induced beta-catenin nuclear translocation in osteoblasts. In Nmp4-null osteoblasts exposed to oscillatory fluid shear stress (OFSS), nuclear translocation of beta-catenin, ERK, Akt, GSK3beta activity, and cyclin D1 expression are all enhanced. OFSS-induced cytoskeletal reorganization and focal adhesion formation are also qualitatively enhanced in Nmp4-null cells.\",\n      \"method\": \"Calvaria-derived osteoblasts from Nmp4-null mice, OFSS mechanical stimulation, nuclear/cytoplasmic fractionation, immunofluorescence, Western blot\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout cells with mechanical stimulation and multiple signaling pathway readouts, single lab\",\n      \"pmids\": [\"20112285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CIZ/NMP4 (ZNF384) binds the RANKL promoter at an identified consensus site, activates RANKL transcription (luciferase assay), and overexpression of CIZ/NMP4 enhances B16 melanoma cell migration. RANKL treatment enhances CIZ/NMP4 expression, establishing a positive feedback loop. siRNA knockdown of CIZ/NMP4 suppresses B16 cell migration in Transwell assays.\",\n      \"method\": \"Transwell migration assay, siRNA knockdown, overexpression, luciferase reporter assay, RANKL promoter binding\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — promoter binding with luciferase plus functional migration assays with both knockdown and overexpression, single lab\",\n      \"pmids\": [\"22307584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CIZ/NMP4 (ZNF384) deficiency in mice suppresses K/BxN serum-induced arthritis severity. CIZ/NMP4 was shown to bind the IL-1β promoter and activate its transcription (established by promoter binding and luciferase assay), and CIZ/NMP4 deficiency reduced arthritis-induced increases in IL-1β, RANKL, and MMP-3 mRNA.\",\n      \"method\": \"CIZ/NMP4 knockout mouse, K/BxN arthritis model, qPCR, histology, promoter binding/luciferase assay\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout with disease model plus promoter-binding mechanistic evidence, single lab\",\n      \"pmids\": [\"26378628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ChIP-seq analysis of Nmp4 (ZNF384) in MC3T3-E1 preosteoblasts, murine embryonic stem cells, and blood cell lines identified Nmp4 target genes enriched for negative regulators of biosynthetic processes. ChIP-seq/gene ontology analysis and mRNA expression profiling in Nmp4-null vs. wild-type MSPCs suggest Nmp4 suppresses bone anabolism in part by regulating IGF-binding protein expression.\",\n      \"method\": \"ChIP-seq, RNA-seq/expression profiling, microCT, histomorphometry, FACS\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq with expression correlation, single lab; ChIP-seq establishes binding sites but downstream mechanism inferred from gene ontology\",\n      \"pmids\": [\"26244796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NMP4 (ZNF384) binds two sites in the AQP5 (aquaporin 5) promoter region (at -1370/-1329 nt and -592/-602 nt) as demonstrated by EMSA. NMP4 overexpression increases AQP5 promoter activity (reporter assays with constructs -469 to -1979 nt) and increases AQP5 mRNA by 2.5-fold in HEK293 cells.\",\n      \"method\": \"EMSA, promoter-reporter assay, overexpression, RT-PCR in HEK293 cells\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and functional reporter assay with mRNA validation, single lab\",\n      \"pmids\": [\"27058007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZNF384 fusion proteins (EP300-ZNF384, SYNRG-ZNF384) exhibit stronger transcriptional activity on SALL4 and ID2 promoters/enhancers than wild-type ZNF384. GST pull-down assay showed ZNF384 fusion proteins bind EP300 (the coactivator) more strongly than wild-type ZNF384. Co-expression of EP300 specifically enhanced transcriptional activities of ZNF384 fusion proteins.\",\n      \"method\": \"GST pull-down, promoter/enhancer-reporter assay (luciferase), EP300 co-expression, transient transfection\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pull-down combined with reporter assays for multiple fusion proteins, single lab\",\n      \"pmids\": [\"31234226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of Nmp4 (ZNF384) in mesenchymal stem/progenitor cells enhances glycolytic conversion during osteogenic differentiation (a key metabolic step in bone anabolism) and increases collagen translation and secretion. RNA-seq of differentiating Nmp4-null MSPCs showed altered expression of >5,000 genes, with elevated matrix gene expression confirmed by biomechanical testing of bone samples.\",\n      \"method\": \"RNA-seq, metabolic assays (glycolysis measurement), collagen secretion assays, biomechanical bone testing, Nmp4-knockout mouse\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout + multiple orthogonal metabolic/secretory/mechanical assays, single lab\",\n      \"pmids\": [\"30645175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NMP4 (ZNF384) binds to promoters and/or conserved non-coding sequences of chemokine genes (Ccl2, Ccl7, Cxcl1) and pro-inflammatory cytokine genes (Il1b, Il6) in mouse lung epithelial cells and macrophages, as demonstrated by ChIP. NMP4-deficient mice show significantly reduced expression of these genes and reduced recruitment of monocytes/neutrophils to the lungs during influenza A (H1N1) infection, with no effect on viral clearance.\",\n      \"method\": \"Nmp4-knockout mouse, influenza infection model, ChIP, qPCR, flow cytometry\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct promoter binding combined with knockout mouse with defined in vivo phenotype and multiple inflammatory readouts\",\n      \"pmids\": [\"32152414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZNF384 binds DNA ends in vitro and is recruited to DNA double-strand breaks (DSBs) in vivo. ZNF384 recruitment to DSBs requires PARP1-dependent chromatin expansion, followed by C2H2 zinc finger binding to exposed DNA. ZNF384 interacts with Ku70/Ku80 via its N-terminus (demonstrated by Co-IP), promoting Ku assembly and recruitment of downstream cNHEJ factors (APLF and XRCC4/LIG4) for efficient DSB repair.\",\n      \"method\": \"In vitro DNA-end binding assay, laser microirradiation/live-cell imaging (recruitment to DSBs), PARP1 inhibition, Co-IP (ZNF384–Ku70/Ku80), domain deletion analysis, NHEJ reporter assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution of DNA end binding, live-cell DSB recruitment assay, Co-IP with domain mapping, functional NHEJ reporter, multiple orthogonal methods\",\n      \"pmids\": [\"34772923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF384 fusion oncoproteins (FO) occupy a subset of predominantly intragenic/enhancer chromatin regions with increased histone 3 lysine acetylation and deregulate expression of hematopoietic stem cell transcription factors. In mouse and human HSPCs expressing ZNF384 FO, myeloid lineage skewing, hematopoietic expansion, and self-renewal occur. In human HSPCs, ZNF384 FO alone drove B/myeloid leukemia. An Ep300::Znf384 knockin mouse model confirmed these phenotypes.\",\n      \"method\": \"Viral expression in mouse/human HSPCs, Ep300::Znf384 knockin mouse, ChIP-seq (H3K27ac), RNA-seq, xenograft model, FLT3 inhibitor treatment in vivo\",\n      \"journal\": \"Blood cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq demonstrating direct chromatin occupancy, knockin mouse model, viral expression in primary cells, multiple orthogonal mechanistic assays\",\n      \"pmids\": [\"35247902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF384-rearranged ALL exclusively activates an intergenic enhancer element at the FLT3 locus through direct binding of the fusion protein, leading to enhancer-promoter looping and FLT3 overexpression. Downregulation of ZNF384 blunts FLT3 activation and decreases cell sensitivity to the FLT3 inhibitor gilteritinib in vitro. In ZNF384-rearranged xenograft models, gilteritinib shows significant anti-leukemia efficacy in vivo.\",\n      \"method\": \"ChIP-seq, chromatin conformation capture (enhancer-promoter looping), shRNA knockdown of ZNF384, luciferase/reporter assay, xenograft mouse model, gilteritinib treatment in vivo\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq + chromatin looping + functional knockdown + in vivo xenograft; multiple orthogonal methods establishing direct mechanistic link\",\n      \"pmids\": [\"36104354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF384 transactivates ZEB1 expression as shown by ChIP-qPCR and luciferase reporter assays, inducing EMT-like phenotype and promoting breast cancer metastasis. ZEB1 in turn upregulates ZNF384 expression by repressing miR-485-5p, forming a positive feedback loop.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, Transwell/scratch migration assays, xenograft mouse model\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirmed direct binding; luciferase reporter validates transactivation; functional migration assays; single lab\",\n      \"pmids\": [\"36100877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Conditional loss of Nmp4 (ZNF384) from Prx1-expressing mesenchymal stem/progenitor cells phenocopies the enhanced PTH-induced trabecular bone increase seen in global Nmp4-null mice. Conditional deletion in mature osteoblasts (BglapCre) failed to increase bone volume or PTH response. Conditional disabling in osteocytes (Dmp1Cre) increased BV/TV without boosting PTH response, defining Prx1-expressing MSPCs as the key cell type for Nmp4-mediated suppression of bone anabolism.\",\n      \"method\": \"Conditional knockout mice (Prx1Cre, BglapCre, Dmp1Cre × Nmp4-floxed), PTH treatment, microCT, histomorphometry, DEXA\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three independent conditional knockout models tested in parallel with PTH challenge; rigorous cell-type-specific attribution of function\",\n      \"pmids\": [\"36321253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EP300-ZNF384 fusion protein transactivates the IL3RA (CD123) promoter by directly binding an A-rich sequence at -222/-234 of the IL3RA promoter, as confirmed by ChIP and luciferase reporter assays. EP300-ZNF384-positive B-ALL cells show elevated membrane CD123 and IL-3-stimulated STAT5 activation; knockdown of IL3RA impaired leukemia cell proliferation in vitro and in vivo.\",\n      \"method\": \"ChIP, luciferase reporter assay, shRNA knockdown of IL3RA, in vitro proliferation assay, in vivo xenograft, STAT5 phosphorylation (Western blot)\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP confirms direct promoter binding; luciferase validates transactivation; functional in vitro and in vivo knockdown; multiple orthogonal methods\",\n      \"pmids\": [\"38566191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RGS1 and CREB5 are identified as direct and common transcriptional target genes of ZNF384 fusion proteins across multiple fusion types. ChIP-qPCR confirmed binding of ZNF384 fusion proteins to regulatory regions of RGS1 and CREB5. ZNF384 fusion-expressing transfectants showed impaired migration toward CXCL12, consistent with RGS1 (an inhibitor of CXCL12-CXCR4 signaling) being upregulated.\",\n      \"method\": \"RNA-seq of transfectants and clinical ALL samples, ChIP-qPCR, CXCL12 migration assay\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR with RNA-seq cross-validation across multiple fusion types and clinical samples; functional migration assay, single lab\",\n      \"pmids\": [\"39015025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF384 (ZNF384) was identified as a regulator of the leukemia epigenome. ChIP-seq data show ZNF384 associates with promoters and enhancers in K562 and GM12878 cells, facilitating increased transcription. ZNF384 is enriched at topologically associating domain (TAD) boundaries and chromatin loops (from Hi-C data). ZNF384 shows significant binding at SINE-Alu elements. CRISPRi knockdown of ZNF384 in K562 cells validated transcriptional regulation.\",\n      \"method\": \"ChIP-seq, RNA-seq, Hi-C chromatin conformation data, CRISPRi knockdown\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq genome-wide data with Hi-C and CRISPRi knockdown validation, single study; bioinformatic analysis but validated with functional knockdown\",\n      \"pmids\": [\"40250193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TCF3::ZNF384 (but not EP300::ZNF384) fusion protein expression in BCP-ALL cell lines confers resistance to dexamethasone-induced apoptosis and significantly upregulates CCND2 (cyclin D2) expression, as shown by oligonucleotide microarray and RT-qPCR. Both fusion proteins downregulate CD10 surface expression. These effects are fusion-partner-dependent.\",\n      \"method\": \"Retrovirus-mediated transduction of BCP-ALL cell lines, annexin-V apoptosis assay, flow cytometry (CD10), oligonucleotide microarray, RT-qPCR\",\n      \"journal\": \"Pediatrics international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional overexpression in cell lines with apoptosis and gene expression readouts; two fusion types compared; single lab\",\n      \"pmids\": [\"40391410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF384 functions as a transcriptional activator of SESN2, as confirmed by ChIP and luciferase reporter assays. In LPS-stimulated lung epithelial cells (BEAS-2B), ZNF384 overexpression reduces ferroptosis and inflammation by activating SESN2-mediated autophagy. Depletion of SESN2 reversed these protective effects.\",\n      \"method\": \"ChIP, luciferase reporter assay, overexpression, siRNA knockdown, ferroptosis markers (MDA, GSH, ROS, Fe2+), ELISA for cytokines\",\n      \"journal\": \"Toxicology in vitro\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay confirm direct binding; functional rescue experiment with SESN2 depletion validates the pathway; single lab\",\n      \"pmids\": [\"40374019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ZNF384 acts as a transcriptional activator of Fibulin-1 (Fbln1) in vascular smooth muscle cells, as identified by DNA pull-down assay and dual-luciferase reporter assay. ZNF384-driven Fbln1 promotes VSMC senescence and collagen deposition through the TGF-β/Smad3 pathway. Fbln1 knockdown ameliorates vascular stiffness in aging and Ang II-infusion mouse models.\",\n      \"method\": \"DNA pull-down assay, dual-luciferase reporter assay, RNA-seq, Fbln1 knockout mouse, Ang II infusion model, pulse wave velocity, histology\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DNA pull-down and reporter assay for direct binding; in vivo mouse models; single lab\",\n      \"pmids\": [\"41816936\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF384 (also known as CIZ/NMP4) is a C2H2-type zinc finger transcription factor that uses zinc fingers 2, 3, and 6 to bind homopolymeric (dA:dT) DNA sequences in the minor groove, thereby regulating transcription of target genes including MMP-1, MMP-3, MMP-7, MMP-13, COL1A1, IL3RA, FLT3, RGS1, CREB5, SESN2, and Fibulin-1; it nucleocytoplasmically shuttles and localizes to focal adhesions and nuclear matrix subdomains (via its zinc finger domain), interacts with p130(Cas) in rat and zyxin in human cells, and in the context of DNA repair acts as a 'Ku-adaptor' by binding DNA ends via its C2H2 motifs and recruiting Ku70/Ku80 through its N-terminus to promote classical non-homologous end-joining; oncogenic fusions of ZNF384 with transcriptional activators (e.g., EP300, TCF3, EWSR1, TAF15) increase EP300 co-activator binding affinity and transcriptional activity on hematopoietic stem cell gene programs, directly activate an intergenic FLT3 enhancer, and drive lineage-ambiguous leukemia by occupying and deregulating enhancers at key hematopoietic regulators.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZNF384 (CIZ/NMP4) is a C2H2 zinc finger transcription factor that recognizes homopolymeric (dA:dT) DNA elements through zinc fingers 2, 3, and 6 binding in the minor groove, and which integrates extracellular and mechanical signals into transcriptional programs governing matrix remodeling, bone anabolism, and inflammation [#0, #4]. It was first identified through its interaction with the SH3 domain of p130(Cas) at focal adhesions, shuttles between cytoplasm and nucleus, and targets its zinc finger domain to nuclear matrix subdomains [#0, #1]; in human cells the p130(Cas) link is indirect, mediated through zyxin [#11]. Depending on promoter context it can activate (MMP-1/3/7, MMP-13, RANKL, IL-1\\u03b2, AQP5) or repress (COL1A1) transcription, with its N-terminal transactivation potential masked in the full-length protein and unmasked allosterically upon DNA binding [#2, #4, #6, #17, #18, #20]. Across multiple knockout models ZNF384 acts as a brake on bone formation, suppressing BMP-2- and PTH-induced osteoblast anabolism specifically within Prx1-expressing mesenchymal stem/progenitor cells, in part by restraining mechanically induced \\u03b2-catenin signaling and glycolytic conversion [#8, #15, #16, #22, #28]. Genome-wide it occupies promoters, enhancers, TAD boundaries, and SINE-Alu elements to regulate transcription [#31], and it directly drives pro-inflammatory chemokine/cytokine programs during influenza infection [#23]. Independently of transcription, ZNF384 functions as a 'Ku-adaptor' in DNA double-strand break repair: after PARP1-dependent chromatin expansion it binds exposed DNA ends through its C2H2 motifs and recruits Ku70/Ku80 via its N-terminus to promote classical non-homologous end-joining [#24]. Recurrent oncogenic fusions of ZNF384 with transcriptional coactivators (EP300, TCF3, EWSR1, TAF15, SYNRG) transform cells via the zinc finger DNA-binding module, bind EP300 with increased affinity, and deregulate hematopoietic stem cell programs and enhancers \\u2014 directly activating an intergenic FLT3 enhancer and the IL3RA/CD123 promoter \\u2014 to drive lineage-ambiguous B/myeloid leukemia [#9, #21, #25, #26, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established ZNF384 as a sequence-specific DNA-binding protein that couples focal adhesion signaling to transcription, answering what kind of molecule it is and what it does.\",\n      \"evidence\": \"Far-Western screen against p130(Cas) SH3, CAST/SELEX, heterokaryon shuttling assay, and promoter-reporter assays for MMP-1/3/7\",\n      \"pmids\": [\"10669742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect nature of the p130(Cas) interaction not resolved in human cells\", \"No structural basis for DNA recognition\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapped the determinant of nuclear localization, showing the zinc finger domain is necessary and sufficient for nuclear import and matrix targeting.\",\n      \"evidence\": \"GFP-fusion immunofluorescence with domain deletions in osteoblasts\",\n      \"pmids\": [\"10972987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Import receptors/NLS sequence not identified\", \"Functional consequence of matrix subdomain targeting unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed ZNF384 can act as a transcriptional repressor as well as activator, establishing context-dependent regulation of COL1A1 via poly(dT) binding and DNA bending.\",\n      \"evidence\": \"Expression-library screening, promoter mutagenesis, antibody disruption and overexpression in UMR-106 osteoblasts\",\n      \"pmids\": [\"11149472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants that switch ZNF384 between activation and repression not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the molecular logic of DNA recognition and activation \\u2014 fingers 2/3/6 bind the minor groove and DNA binding allosterically unmasks the otherwise repressed N-terminal/poly(QA) transactivation function.\",\n      \"evidence\": \"GAL4 fusion transactivation, zinc-finger deletion mutagenesis, in vitro DNA binding and reporter assays\",\n      \"pmids\": [\"11867614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the allosteric activation not available\", \"Cofactors recruited by the unmasked activation domain unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"First linked ZNF384 to leukemia via EWSR1 and TAF15 fusions, showing they transform cells independently of normal target-gene regulation.\",\n      \"evidence\": \"RT-PCR cloning of fusion transcripts and NIH3T3 focus formation with target gene expression analysis\",\n      \"pmids\": [\"12359745\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of transformation not yet linked to specific target genes\", \"Single transformation assay system\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established ZNF384 as a physiological suppressor of bone mass acting through inhibition of BMP signaling, defining its in vivo role.\",\n      \"evidence\": \"CIZ-knockout mouse histomorphometry, BMP-2 calvarial injection, and bone marrow differentiation assays\",\n      \"pmids\": [\"15781586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target in the BMP/Smad pathway not defined\", \"Whether suppression is transcriptional or via protein interaction unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed the zinc fingers are obligatory for the oncogenic activity of fusions, demonstrating transformation requires ZNF384 DNA binding.\",\n      \"evidence\": \"Domain-deletion mutagenesis with NIH3T3 focus formation and MMP7 luciferase reporter for TCF3/VP16 fusions\",\n      \"pmids\": [\"15669012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous target genes driving transformation not identified at this stage\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revised the interactome for human ZNF384, finding zyxin (not direct p130CAS), PCBP1, and vimentin as partners.\",\n      \"evidence\": \"Yeast two-hybrid screening in human cells\",\n      \"pmids\": [\"16510139\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Yeast two-hybrid only with no orthogonal validation of the interactions\", \"Functional consequence of zyxin/PCBP1/vimentin binding untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected ZNF384 to mechanotransduction, showing it restrains mechanically induced \\u03b2-catenin and growth-factor signaling in osteoblasts.\",\n      \"evidence\": \"Nmp4-null osteoblasts under oscillatory fluid shear stress with fractionation, Western blot, and immunofluorescence (also EMSA-based MMP-13 mechanoregulation [#12], unloading models [#13])\",\n      \"pmids\": [\"20112285\", \"17455210\", \"17301008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism linking ZNF384 to \\u03b2-catenin nuclear entry unknown\", \"Upstream mechanosensor coupling to ZNF384 undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended ZNF384 function to inflammation and innate immunity, showing direct activation of pro-inflammatory and chemokine gene programs.\",\n      \"evidence\": \"ChIP and knockout-mouse phenotyping in K/BxN arthritis and influenza infection models with cytokine/chemokine readouts\",\n      \"pmids\": [\"26378628\", \"32152414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals that activate ZNF384 inflammatory targets in vivo not defined\", \"Cell-type-specific contributions partially resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined cell-type-specific and metabolic mechanisms of bone suppression, localizing ZNF384 function to Prx1+ MSPCs and linking it to glycolysis and collagen output.\",\n      \"evidence\": \"Conditional knockout mice (Prx1/Bglap/Dmp1 Cre), RNA-seq, metabolic and biomechanical assays with PTH challenge\",\n      \"pmids\": [\"36321253\", \"30645175\", \"19189321\", \"26244796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets governing glycolytic switch not pinpointed\", \"Mechanism of PTH-response modulation unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mechanistically explained why fusion oncoproteins are more potent \\u2014 they bind the EP300 coactivator with increased affinity and hyperactivate target promoters/enhancers.\",\n      \"evidence\": \"GST pull-down and enhancer/promoter reporter assays for EP300- and SYNRG-ZNF384 fusions\",\n      \"pmids\": [\"31234226\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide chromatin consequences not yet mapped at this stage\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a transcription-independent role in DNA repair, defining ZNF384 as a Ku-adaptor that bridges DNA ends to the NHEJ machinery.\",\n      \"evidence\": \"In vitro DNA-end binding, laser microirradiation recruitment, PARP1 inhibition, Co-IP with Ku70/Ku80, domain mapping and NHEJ reporter\",\n      \"pmids\": [\"34772923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How transcriptional and repair functions are coordinated/partitioned unknown\", \"Whether repair role is altered in fusion-bearing leukemia not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established the genome-wide oncogenic mechanism: fusion proteins occupy enhancers, increase H3K27ac, deregulate HSC transcription factors, and directly activate a FLT3 enhancer to drive lineage-ambiguous leukemia.\",\n      \"evidence\": \"ChIP-seq, chromatin conformation capture, viral expression and Ep300::Znf384 knockin mouse, xenografts with FLT3 inhibitor treatment\",\n      \"pmids\": [\"35247902\", \"36104354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full target-gene network across fusion types not exhaustively defined\", \"Determinants of B vs myeloid lineage skewing incomplete\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified additional direct fusion target genes (IL3RA/CD123, RGS1, CREB5) that confer therapeutically actionable and migration phenotypes.\",\n      \"evidence\": \"ChIP/ChIP-qPCR, luciferase reporters, shRNA knockdown, STAT5 signaling, migration assays and xenografts across multiple fusion types\",\n      \"pmids\": [\"38566191\", \"39015025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each target to leukemogenesis not ranked\", \"RGS1/CREB5 functional validation limited to migration assays\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed fusion-partner identity dictates distinct downstream phenotypes (e.g., TCF3 fusion-specific dexamethasone resistance and CCND2 upregulation).\",\n      \"evidence\": \"Retroviral transduction of BCP-ALL lines, apoptosis assays, flow cytometry, microarray and RT-qPCR; plus genome-wide CRISPRi/ChIP-seq/Hi-C epigenome mapping\",\n      \"pmids\": [\"40391410\", \"40250193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of partner-specific differences not defined\", \"Generalizability of K562/GM12878 epigenome findings to leukemia subtypes unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Expanded the cytoprotective/disease repertoire, showing ZNF384 activates SESN2-mediated autophagy and Fibulin-1-driven vascular pathways.\",\n      \"evidence\": \"ChIP/DNA pull-down, luciferase reporters, rescue experiments, ferroptosis markers, and in vivo vascular stiffness models\",\n      \"pmids\": [\"40374019\", \"41816936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conditions activating these programs physiologically unclear\", \"Single-lab findings without independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ZNF384 selects between transcriptional activation, repression, and DNA-end repair functions \\u2014 and how fusion partners reprogram its genomic targeting \\u2014 remains mechanistically unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of DNA recognition or coactivator engagement\", \"Coordination between repair and transcription roles unknown\", \"Determinants of activation-vs-repression switching undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 4, 6, 20, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 4, 17, 18, 23, 29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 4, 23, 25]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [25, 26, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [23, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"p130Cas (BCAR1)\", \"zyxin (ZYX)\", \"PCBP1\", \"vimentin (VIM)\", \"EP300\", \"Ku70 (XRCC6)\", \"Ku80 (XRCC5)\", \"COL1A1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}